Cryoablation of bone metastases in thyroid and adrenocortical cancers

This study looked at a minimally invasive treatment called cryoablation, which uses extreme cold to destroy cancer that has spread to the bones, in people with thyroid (including MTC) or adrenocortical cancer.

Click here for more information

Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A

This study followed people with MEN2A who had their thyroid removed to understand how often long-term blood tests for calcitonin are really needed.

Click here for more information

The prostate is a common site of disease in patients with MEN2B and MTC

A recent study looked at young men with MEN2B (also known as MEN3), which causes medullary thyroid cancer.  Doctors found that problems in the prostate were more common than previously thought, even in teenagers.

Click here for more information

National Cancer Plan for England Launched

Wednesday 4th February 2026, marked as World Cancer Day, saw the publication of the detailed National Cancer Plan for England by the Department of Health & Social Care

Click here to learn more

MEN2B and Family Planning Survey

In collaboration with clinicians at St Bartholomew’s Hospital in London, AMEND would like to learn more about attitudes and experiences of those affected by MEN2B (also known as MEN3) to family planning.

Click to learn more and to participate

New MEN1 App Launched

Today, AMEND has launched an app for MEN1 members ensuring that information is always at hand, even if offline.  The app replaces the traditional, expensive, and slow-to-receive hardcopy MEN1 Member Pack.

Click here for more information

Grant from The Albert Hunt Trust

We are hugely grateful to the Trustees of The Albert Hunt Trust who have granted AMEND £5,000 towards 2026 core costs.

2026 Peer Support Meetings

We are pleased to confirm the dates for our 2026 Peer Support Meetings for those with MEN or PPGL syndromes.  You can book now to connect with others.

Click here to view dates and to book

New Phase 3 Clinical Trial for Hyperinsulinism Drug

The upLIFT study, phase 3 clinical trial of ersodetug for tumour hyperinsulinism (HI), a drug from Rezolute (a late-stage rare disease company) is now enrolling participants through 2 UK centres.

Click to learn more

MEN2B Added to Generation Study

MEN2B RET mutation 918 to be added to the Genomics England’s Generation Study from March 2026.

Learn more